LLY

Eli Lilly and Company

LLY.US lilly.com
1,123.00
-1.21 (-0.11%)
USD · NYSE
52-week range
707.59
1,292.65
Trading at 71% of the 52-week range
Market Cap
1.00T
P/E Ratio
37.75
Forward P/E
23.81
Book Value
38.00
Div. Yield
0.57%
% Institutions
85.43%
% Insiders
0.157%

1 Year

+49.8%

3 Year

+92.5%

10 Year

+1,560.3%
Description

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Company Information

Company Name
Eli Lilly and Company
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYSE
ISIN: US5324571083
CIK: 0000059478
CUSIP: 532457108
Currency: USD
Full Time Employees: 50,000
Phone: 317 276 2000
Website: lilly.com
Fiscal Year End: December
IPO Date: Jan 13, 1978
Description:

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Address:

Lilly Corporate Center, Indianapolis, IN, United States, 46285

People

Directors & Officers

Name Title Year Born
Mr. David A. Ricks Chairman, President & CEO 1968
Mr. Lucas E. Montarce Executive VP & CFO 1977
Dr. Daniel M. Skovronsky M.D., Ph.D. Chief Scientific & Product Officer and President of Lilly Research Laboratories 1973
Ms. Anat Hakim J.D. Executive VP, General Counsel & Secretary 1969
Mr. Jacob S. Van Naarden Executive VP, President of Lilly Oncology & Head of Corporate Business Development 1985
Mr. Donald A. Zakrowski Senior VP of Finance & Chief Accounting Officer NA
Mr. Diogo Rau Executive VP and Chief Information & Digital Officer 1975
Mr. Michael Czapar Senior Vice President of Investor Relations NA
Mr. Eric Dozier Executive VP & Chief People Officer 1967
Mr. Ilya Yuffa Executive VP and President of Lilly USA & Global Customer Capabilities 1975

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 13, 2026 Gilbert Ray Cisneros, Jr. N/A Sale N/A $985.10 N/A
Feb 26, 2026 David Taylor N/A Purchase N/A $1.02K N/A
Feb 13, 2026 Angus S. King Jr. N/A Sale N/A $1.04K N/A
Feb 09, 2026 David Taylor N/A Sale N/A $1.05K N/A
Jan 23, 2026 Ro Khanna N/A Purchase N/A $1.07K N/A
Jan 16, 2026 David Taylor N/A Sale N/A $1.04K N/A
Dec 29, 2025 Angus S. King Jr. N/A Purchase N/A $1.08K N/A
Dec 29, 2025 Markwayne Mullin N/A Purchase N/A $1.08K N/A
Dec 18, 2025 Julie Johnson N/A Sale N/A $1.06K N/A
Dec 10, 2025 David Taylor N/A Sale N/A $993.51 N/A
Nov 21, 2025 John Boozman N/A Sale N/A $1.06K N/A
Nov 18, 2025 Gilbert Ray Cisneros, Jr. N/A Purchase N/A $1.03K N/A
Nov 13, 2025 Julie Johnson N/A Sale N/A $1.02K N/A
Nov 07, 2025 Ro Khanna N/A Sale N/A $923.35 N/A
Oct 24, 2025 Shelley Moore Capito N/A Purchase N/A $825.86 N/A
Sep 23, 2025 Val T. Hoyle N/A Sale N/A $747.29 N/A
Aug 26, 2025 Ro Khanna N/A Sale N/A $734.93 N/A
Aug 22, 2025 John Boozman N/A Purchase N/A $710.73 N/A
Aug 14, 2025 Julie Johnson N/A Sale N/A $685.27 N/A
Aug 14, 2025 David Taylor N/A Purchase N/A $685.27 N/A

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Lilly Endowment Inc 90.38M Jun 30, 2026 10.14% $100.00 -1.65%
BlackRock Inc 66.38M Mar 31, 2026 7.45% $1.07 -0.62%
Vanguard Capital Management, LLC 53.36M Mar 31, 2026 5.99% $1.21 0.00%
PNC Financial Services Group Inc 51.33M Mar 31, 2026 5.76% $27.26 -0.01%
State Street Corp 35.61M Mar 31, 2026 4.00% $1.13 0.70%
FMR Inc 26.34M Mar 31, 2026 2.96% $1.28 2.41%
Vanguard Portfolio Management, LLC 20.98M Mar 31, 2026 2.35% $1.01 0.00%
Capital Research Global Investors 20.87M Jun 30, 2026 2.34% $3.49 -15.26%
Geode Capital Management, LLC 20.19M Mar 31, 2026 2.27% $1.15 1.93%
Capital World Investors 15.90M Jun 30, 2026 1.78% $2.25 1.80%
Morgan Stanley - Brokerage Accounts 15.44M Mar 31, 2026 1.73% $0.86 -1.00%
T. Rowe Price Associates, Inc. 13.99M Mar 31, 2026 1.57% $1.49 -6.16%
JPMorgan Chase & Co 13.70M Mar 31, 2026 1.54% $0.78 5.39%
NORGES BANK 11.47M Jun 30, 2026 1.29% $1.37 -5.00%
Bank of America Corp 11.13M Mar 31, 2026 1.25% $0.75 0.18%
Wellington Management Company LLP 11.00M Jun 30, 2026 1.23% $2.27 -18.08%
State Farm Mutual Automobile Ins Co 10.76M Jun 30, 2026 1.21% $8.83 0.00%
PRIMECAP Management Company 9.17M Jun 30, 2026 1.03% $6.51 -0.55%
Northern Trust Corp 8.83M Mar 31, 2026 0.99% $1.07 -0.09%
UBS Asset Mgmt Americas Inc 7.07M Mar 31, 2026 0.79% $1.35 8.81%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 26.99M 3.03% ▲ 0.29% Jul 31, 2026
2 Vanguard 500 Index Investor 20.77M 2.33% ▲ 1.06% Jul 31, 2026
3 iShares Core S&P 500 ETF 10.53M 1.18% ▼ 0.16% Aug 31, 2026
4 Fidelity 500 Index 10.23M 1.15% ▲ 0.80% Jul 31, 2026
5 State Street® SPDR® S&P 500® ETF 9.70M 1.09% ▲ 0.02% Aug 31, 2026
6 Vanguard MStar Growth Index Investor 8.81M 0.99% ▼ 0.60% Jul 31, 2026
7 Capital Group Growth Fnd of Amer Comp 8.36M 0.94% ▼ 16.47% Jun 30, 2026
8 American Funds Growth Fd of Amer A 8.36M 0.94% ▼ 16.47% Jun 30, 2026
9 State Street®HlthCrSelSectSPDR®ETF 5.65M 0.63% ▼ 0.23% Aug 31, 2026
10 Vanguard PRIMECAP Inv 5.41M 0.61% ▼ 0.54% Jun 30, 2026

Financial Highlights

Market Cap: $1,002.50B
EBITDA: $41.71B
P/E Ratio: $37.75
PEG Ratio: $1.09
Book Value: $38.00
Dividend/Share: $6.46
Dividend Yield: 0.57%
Earnings/Share: $29.78
Profit Margin: 33.53%
Operating Margin: 54.22%
ROA (TTM): 20.36%
ROE (TTM): 102.29%
Revenue (TTM): $79.67B
Revenue/Share (TTM): $89.02
Earnings Growth (YOY): 26.20%
Revenue Growth (YOY): 47.70%

Valuation Metrics

Enterprise Value: $1,047.76B
Trailing P/E: 37.75
Forward P/E: 23.81

Shares Statistics

Shares Outstanding: 891.74M
Shares Float: 888.95M
% Insiders: 0.157%
% Institutions: 85.43%
Short % Float: 0.74%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$65.18B
Cost of Goods Sold
adjust
$-10.56B
Gross Profit
subtotal
$54.62B
SG&A
adjust
$-11.09B
R&D
adjust
$-13.34B
Other Operating Expense
adjust
$-487.50M
Operating Income
subtotal
$29.70B
Other / Non-Operating Items
adjust
$-9.06B
Net Income
subtotal
$20.64B

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about LLY.US!